News & Events

Armune BioScience, Inc. Announces Closing of Series A Round of Financing

KALAMAZOO, MICH. March 30th, 2016 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the final close of its $4 million Series A financing. “We are pleased to successfully complete our Series A financing,” said David Esposito, […]

Armune BioScience Expands Access to Apifiny with ARCpoint Labs

KALAMAZOO, MI February 10, 2016 – Armune BioScience signed a definitive agreement with ARCpoint Labs to offer Apifiny® across their network of laboratory service centers across the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny order volume […]

Armune BioScience Expands Access to Apifiny with Fortified Provider Network

KALAMAZOO, MI January 27, 2016 – Armune BioScience, an emerging leader in break-through cancer diagnostics, has secured a contractual agreement for Apifiny® with Fortified Provider Network, one of the fastest growing national provider networks in the United States. Under the terms of the agreement, Armune is established as a preferred provider and its Apifiny test […]

Armune BioScience Secures Contract for Apifiny with USA Managed Care Organization to Expand Access to Apifiny

KALAMAZOO, MI January 26, 2016 – Armune BioScience, an emerging leader in break-through cancer diagnostics, has secured a contractual agreement for Apifiny with USA Managed Care Organization, the largest, most comprehensive, privately-held preferred provider organization (PPO) in America. Under the terms of the agreement, Armune is established as a preferred provider, and its Apifiny test […]

Armune BioScience Secures Contract For Apifiny With America’s Choice Provider Network To Expand Access To Apifiny

KALAMAZOO, MI (January 25, 2016). Armune BioScience, an emerging leader in break-through cancer diagnostics, has secured a contractual agreement for Apifiny with America’s Choice Provider Network (ACPN), a leading preferred provider organization (PPO). Under the terms of the agreement, Armune is established as a preferred provider, and its Apifiny test will be covered by over […]

Armune BioScience Expands Access To Apifiny With Accu Reference Medical Lab

KALAMAZOO, MI (January 19, 2016). Armune BioScience signed a definitive agreement with Accu Reference Medical Laboratory to offer Apifiny® to their rapidly growing physician account base in over 15 states. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny […]

Armune BioScience Announces Agreement Retaining Mavericks Capital as Advisor and Investment Bank

Kalamazoo, MI (January 11, 2016). Armune BioScience, Inc., a medical diagnostics company that is developing and commercializing proprietary blood tests for prostate, lung and breast cancers, announced today that the company has entered into a definitive agreement with Mavericks Capital retaining them as the Company’s advisor and investment bank. In April of 2015, Armune BioScience […]